• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Coya Therapeutics Inc.

    5/16/25 5:05:18 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COYA alert in real time by email
    DEFA14A 1 d874014ddefa14a.htm DEFA14A DEFA14A
     
     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    COYA THERAPEUTICS, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

     

     2025 Stockholder Meeting Notice    LOGO

    Important Notice Regarding the Availability of Proxy Materials for the

    Coya Therapeutics, Inc. Stockholder Meeting to be Held on June 26, 2025.

    Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important!

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 Proxy Statement; Annual Report on Form 10-K for the Year Ended December 31, 2024 are available at:

     

    www.envisionreports.com/COYA

     

     

    LOGO

     

    Easy Online Access – View your proxy materials and vote.

     

      Step 1:    Go to www.envisionreports.com/COYA.
      Step 2:    Click on Cast Your Vote or Request Materials.
      Step 3:    Follow the instructions on the screen to log in.
      Step 4:    Make your selections as instructed on each screen for your delivery preferences.
      Step 5:    Vote your shares.

    When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.

     

     

     

    LOGO   Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 26, 2025 to facilitate timely delivery.

     

    ⬛   2NOT   COY   LOGO

    045JMB


     
     2025 Stockholder Meeting Notice

    Coya Therapeutics, Inc. Annual Meeting of Stockholders will be held on June 26, 2025, virtually at meetnow.global/MJYXQX7, at 12:00 p.m. Central Time.

    Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations.

    The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposal 2:

     

      1.

    Election of Directors:

    01 - Howard Berman, Ph.D.

    02 - Arun Swaminathan, Ph.D.

    03 - Ann Lee, Ph.D.

      2.

    Ratify the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent public accounting firm for the year ending December 31, 2025

    PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you.

     

     

     

     

    LOGO   

    Here’s how to order a copy of the proxy materials and select delivery preferences:

     

    Current and future delivery requests can be submitted using the options below.

     

    If you request an email copy, you will receive an email with a link to the current meeting materials.

     

    PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

     

    –   Internet – Go to www.envisionreports.com/COYA. Click Cast Your Vote or Request Materials.

     

    –   Phone – Call us free of charge at 1-866-641-4276.

     

    –   Email – Send an email to [email protected] with “Proxy Materials Coya Therapeutics, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

     

    To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 26, 2025.

    Get the next $COYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COYA

    DatePrice TargetRatingAnalyst
    12/4/2024$15.00Buy
    D. Boral Capital
    More analyst ratings

    $COYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in the H.C. Wainwright 3rd Annual BioConnect Conference being held in New York City on Tuesday, May 20, 2025. Chief Executive Officer Arun Swaminathan, Ph.D. will participate in a fireside chat and be available for one-on-one meetings throughout the event. Event: H. C. Wainwright 3rd Annual BioConnect Investor Conference Date: May 20, 2025 Time: 12:30pm ET Location: Nasdaq World Headquarters (151 West 43rd Street) Webcast: https://journey.ct

      5/16/25 10:53:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2025. Recent Corporate Highlights Announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose (LD) IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD) Published results of a study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA), Coya's investigational biologic combination to suppress pro-inflammatory myeloid ce

      5/13/25 8:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in two upcoming conferences in May 2025. Chief Executive Officer Arun Swaminathan, Ph.D. and Chief Financial Officer David Snyder will be available for one-on-one meetings with registered investors of the following conferences: Event: D. Boral Capital Inaugural Global Conference Date: May 14, 2025 Registration: Contact John Perez at [email protected] Location: The Plaza Hotel 768 Fifth Avenue New York, NY 10019   Event:

      5/8/25 8:15:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COYA
    Leadership Updates

    Live Leadership Updates

    See more
    • Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

      Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

      5/8/25 5:00:00 AM ET
      $COYA
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

      BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

      4/17/25 7:00:00 AM ET
      $AVIR
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.

      Secretary Ross has over 55 years' experience as a business leader, banker, and investor and is the former Chairman and Chief Strategy Officer of WL Ross & Co. Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Secretary Wilbur Ross to its board of directors, effective immediately. Coya intends to leverage Secretary Ross's extensive experience in both the business and investment community to help guide strategic partnering activities, capital markets initiatives and drug development programs. S

      12/20/23 8:30:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Weinand Dieter

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      2/25/25 9:30:04 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ross Wilbur L Jr

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      2/25/25 9:30:03 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lee Ann

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      2/25/25 9:30:08 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Coya Therapeutics with a new price target

      D. Boral Capital initiated coverage of Coya Therapeutics with a rating of Buy and set a new price target of $15.00

      12/4/24 7:30:44 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COYA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Coya Therapeutics Inc.

      DEFA14A - Coya Therapeutics, Inc. (0001835022) (Filer)

      5/16/25 5:05:18 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Coya Therapeutics Inc.

      DEF 14A - Coya Therapeutics, Inc. (0001835022) (Filer)

      5/16/25 5:01:09 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Coya Therapeutics Inc.

      10-Q - Coya Therapeutics, Inc. (0001835022) (Filer)

      5/13/25 8:14:38 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

      SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

      11/12/24 3:37:54 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

      SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

      11/4/24 1:27:32 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

      SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

      11/4/24 11:42:58 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Snyder David S bought $12,934 worth of shares (1,800 units at $7.19), increasing direct ownership by 26% to 8,800 units (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/14/24 6:08:32 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Swaminathan Arun bought $36,797 worth of shares (5,000 units at $7.36), increasing direct ownership by 100% to 10,000 units (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/13/24 4:05:16 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Grossman Fred bought $19,973 worth of shares (2,710 units at $7.37) (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/12/24 6:03:34 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COYA
    Financials

    Live finance-specific insights

    See more
    • Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results will be presented simultaneously via a poster on Tuesday, October 29, at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The Phase 2 study was led by KOLs Dr. Alireza Faridar and Dr. Stanley

      10/28/24 8:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the third quarter ended September 30, 2023, and provided a clinical and business update. Q3 2023 and Recent Highlights Completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of Low Dose IL-2 in patients with mild-to-moderate Alzheimer's Disease (AD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at the Houston Methodist Hospital and is funded by the Gates Foundation and Alzheimer's As

      11/8/23 9:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update. Q2 2023 and Recent Highlights Presented positive results from a proof-of-concept (PoC), open-label, investigator-initiated clinical study of low dose interleukin-2 (ld IL-2) + CTLA4 Ig in Amyotrophic Lateral Sclerosis (ALS) illustrating enhancement of Treg function during the treatment period, halting of disease progression at 24 weeks and minimal decline a

      8/8/23 7:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care